 Joshua Melson
Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 29 | 2023 | 128 | 12.970 |
Why?
| | Adenoma | 16 | 2023 | 63 | 9.640 |
Why?
| | Colonoscopy | 30 | 2023 | 90 | 9.000 |
Why?
| | Colonic Polyps | 12 | 2023 | 37 | 6.360 |
Why?
| | Early Detection of Cancer | 14 | 2023 | 99 | 3.750 |
Why?
| | Neoplasms, Second Primary | 5 | 2022 | 40 | 3.050 |
Why?
| | Mass Screening | 7 | 2023 | 203 | 2.320 |
Why?
| | DNA Methylation | 5 | 2022 | 169 | 1.980 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2022 | 22 | 1.750 |
Why?
| | Capsule Endoscopy | 2 | 2021 | 5 | 1.580 |
Why?
| | Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 1.450 |
Why?
| | Humans | 51 | 2023 | 32988 | 1.250 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2018 | 40 | 1.240 |
Why?
| | Adenomatous Polyps | 3 | 2017 | 7 | 1.200 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2021 | 14 | 1.190 |
Why?
| | Colon | 4 | 2018 | 160 | 1.170 |
Why?
| | Guideline Adherence | 2 | 2016 | 78 | 1.080 |
Why?
| | Barrett Esophagus | 2 | 2020 | 18 | 0.940 |
Why?
| | Upper Gastrointestinal Tract | 1 | 2022 | 2 | 0.900 |
Why?
| | Gastroenterology | 3 | 2019 | 17 | 0.900 |
Why?
| | Esophageal Neoplasms | 2 | 2020 | 61 | 0.890 |
Why?
| | Middle Aged | 21 | 2021 | 11219 | 0.880 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2022 | 4 | 0.880 |
Why?
| | Intestine, Small | 1 | 2021 | 37 | 0.790 |
Why?
| | Esophageal and Gastric Varices | 1 | 2020 | 2 | 0.770 |
Why?
| | Carcinoma | 2 | 2022 | 77 | 0.750 |
Why?
| | Poverty Areas | 1 | 2019 | 10 | 0.710 |
Why?
| | Censuses | 1 | 2019 | 8 | 0.710 |
Why?
| | Quality of Health Care | 2 | 2022 | 151 | 0.710 |
Why?
| | Aged | 17 | 2021 | 10542 | 0.650 |
Why?
| | Male | 20 | 2021 | 17726 | 0.650 |
Why?
| | Female | 20 | 2021 | 18423 | 0.640 |
Why?
| | Residence Characteristics | 1 | 2019 | 228 | 0.620 |
Why?
| | Population Surveillance | 1 | 2018 | 126 | 0.610 |
Why?
| | Cecum | 1 | 2016 | 10 | 0.610 |
Why?
| | Lymphoid Tissue | 1 | 2016 | 19 | 0.600 |
Why?
| | Pancreatic Neoplasms | 2 | 2020 | 176 | 0.590 |
Why?
| | Adenocarcinoma | 2 | 2019 | 231 | 0.590 |
Why?
| | Clinical Competence | 2 | 2016 | 284 | 0.590 |
Why?
| | Unnecessary Procedures | 1 | 2016 | 29 | 0.580 |
Why?
| | Colorectal Surgery | 1 | 2015 | 7 | 0.550 |
Why?
| | Retrospective Studies | 9 | 2023 | 3835 | 0.540 |
Why?
| | Radiography, Thoracic | 1 | 2015 | 40 | 0.540 |
Why?
| | Colonic Neoplasms | 3 | 2022 | 81 | 0.540 |
Why?
| | Hyperplasia | 3 | 2021 | 25 | 0.520 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2013 | 19 | 0.490 |
Why?
| | Patient Compliance | 1 | 2015 | 200 | 0.470 |
Why?
| | Risk Factors | 5 | 2021 | 2762 | 0.470 |
Why?
| | Diagnostic Errors | 1 | 2013 | 48 | 0.460 |
Why?
| | Prospective Studies | 5 | 2023 | 2002 | 0.400 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 388 | 0.400 |
Why?
| | Intestinal Mucosa | 4 | 2022 | 231 | 0.390 |
Why?
| | Colectomy | 1 | 2010 | 32 | 0.390 |
Why?
| | Cohort Studies | 5 | 2018 | 2077 | 0.380 |
Why?
| | Colitis, Ulcerative | 1 | 2010 | 78 | 0.370 |
Why?
| | Neoplasm Staging | 6 | 2020 | 457 | 0.370 |
Why?
| | Chi-Square Distribution | 3 | 2015 | 177 | 0.340 |
Why?
| | Biopsy | 3 | 2021 | 277 | 0.320 |
Why?
| | United States | 4 | 2020 | 2632 | 0.320 |
Why?
| | Logistic Models | 3 | 2015 | 474 | 0.310 |
Why?
| | Incidence | 3 | 2019 | 840 | 0.310 |
Why?
| | Gastrointestinal Diseases | 1 | 2007 | 47 | 0.310 |
Why?
| | Graft vs Host Disease | 1 | 2007 | 60 | 0.310 |
Why?
| | Area Under Curve | 2 | 2019 | 77 | 0.300 |
Why?
| | Esophagoscopy | 3 | 2021 | 17 | 0.290 |
Why?
| | Academic Medical Centers | 2 | 2016 | 162 | 0.250 |
Why?
| | Treatment Outcome | 4 | 2023 | 4036 | 0.250 |
Why?
| | Surgical Instruments | 1 | 2023 | 30 | 0.230 |
Why?
| | Severity of Illness Index | 1 | 2007 | 1242 | 0.220 |
Why?
| | Benchmarking | 1 | 2022 | 42 | 0.220 |
Why?
| | Risk Assessment | 3 | 2020 | 814 | 0.220 |
Why?
| | Esophageal pH Monitoring | 1 | 2021 | 2 | 0.220 |
Why?
| | Prognosis | 4 | 2018 | 1011 | 0.210 |
Why?
| | Zenker Diverticulum | 1 | 2021 | 1 | 0.210 |
Why?
| | MicroRNAs | 1 | 2022 | 62 | 0.210 |
Why?
| | Esophagus | 1 | 2021 | 60 | 0.210 |
Why?
| | Endosonography | 2 | 2020 | 15 | 0.200 |
Why?
| | Gastrointestinal Transit | 1 | 2021 | 14 | 0.200 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 27 | 0.200 |
Why?
| | Adult | 6 | 2020 | 9848 | 0.200 |
Why?
| | Pancreatitis, Chronic | 1 | 2020 | 2 | 0.200 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2021 | 29 | 0.200 |
Why?
| | Pancreatic Cyst | 1 | 2020 | 5 | 0.200 |
Why?
| | Ikaros Transcription Factor | 1 | 2020 | 2 | 0.200 |
Why?
| | Transaminases | 1 | 2020 | 9 | 0.200 |
Why?
| | Observer Variation | 1 | 2021 | 142 | 0.200 |
Why?
| | Gastroparesis | 1 | 2020 | 3 | 0.200 |
Why?
| | Magnets | 1 | 2020 | 2 | 0.190 |
Why?
| | Epithelial Cells | 2 | 2013 | 107 | 0.190 |
Why?
| | Feasibility Studies | 1 | 2021 | 282 | 0.190 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2019 | 6 | 0.190 |
Why?
| | Bariatric Surgery | 1 | 2020 | 45 | 0.180 |
Why?
| | Appointments and Schedules | 1 | 2019 | 15 | 0.180 |
Why?
| | Aged, 80 and over | 5 | 2020 | 5249 | 0.180 |
Why?
| | Databases, Factual | 1 | 2021 | 393 | 0.180 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2018 | 2 | 0.170 |
Why?
| | Precancerous Conditions | 1 | 2018 | 27 | 0.170 |
Why?
| | ROC Curve | 1 | 2019 | 155 | 0.170 |
Why?
| | Forecasting | 1 | 2019 | 136 | 0.170 |
Why?
| | Quality Improvement | 1 | 2020 | 173 | 0.170 |
Why?
| | Colonoscopes | 1 | 2018 | 1 | 0.170 |
Why?
| | Genetic Testing | 1 | 2018 | 77 | 0.160 |
Why?
| | Reproducibility of Results | 1 | 2021 | 893 | 0.160 |
Why?
| | Referral and Consultation | 1 | 2018 | 102 | 0.160 |
Why?
| | Sex Factors | 2 | 2018 | 548 | 0.150 |
Why?
| | CpG Islands | 1 | 2017 | 53 | 0.150 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 81 | 0.150 |
Why?
| | Brain Neoplasms | 1 | 2018 | 178 | 0.150 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2017 | 44 | 0.150 |
Why?
| | Portal Vein | 1 | 2017 | 50 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 91 | 0.150 |
Why?
| | Ultrasonography, Interventional | 1 | 2017 | 75 | 0.150 |
Why?
| | Documentation | 1 | 2016 | 34 | 0.140 |
Why?
| | Age Factors | 2 | 2018 | 932 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 81 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2017 | 122 | 0.140 |
Why?
| | Hospitals, Community | 1 | 2015 | 20 | 0.140 |
Why?
| | Rectal Neoplasms | 1 | 2015 | 29 | 0.130 |
Why?
| | Microsatellite Instability | 1 | 2014 | 9 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2013 | 694 | 0.130 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 592 | 0.130 |
Why?
| | Analysis of Variance | 1 | 2015 | 358 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 1058 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 90 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 626 | 0.120 |
Why?
| | Internship and Residency | 1 | 2016 | 209 | 0.120 |
Why?
| | Mast Cells | 1 | 2013 | 42 | 0.120 |
Why?
| | Colitis | 1 | 2013 | 39 | 0.110 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 51 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 71 | 0.110 |
Why?
| | Macrophages | 1 | 2013 | 138 | 0.110 |
Why?
| | Time Factors | 1 | 2016 | 1873 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 156 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 899 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2013 | 2053 | 0.080 |
Why?
| | Transplantation Conditioning | 1 | 2007 | 47 | 0.080 |
Why?
| | Immunohistochemistry | 2 | 2019 | 471 | 0.080 |
Why?
| | Drug Resistance | 1 | 2007 | 65 | 0.080 |
Why?
| | Diarrhea | 1 | 2007 | 49 | 0.080 |
Why?
| | Acute Disease | 1 | 2007 | 258 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 113 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 297 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2007 | 166 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2007 | 128 | 0.070 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 92 | 0.070 |
Why?
| | Apoptosis | 1 | 2007 | 288 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2010 | 1485 | 0.070 |
Why?
| | Reoperation | 1 | 2010 | 970 | 0.070 |
Why?
| | Fecal Incontinence | 1 | 2005 | 9 | 0.070 |
Why?
| | Occult Blood | 1 | 2023 | 3 | 0.060 |
Why?
| | Geriatric Assessment | 1 | 2005 | 228 | 0.060 |
Why?
| | Feces | 1 | 2023 | 98 | 0.060 |
Why?
| | Carcinogenesis | 1 | 2022 | 26 | 0.050 |
Why?
| | Manometry | 1 | 2021 | 25 | 0.050 |
Why?
| | Endoscopes | 1 | 2021 | 14 | 0.050 |
Why?
| | Pylorus | 1 | 2020 | 2 | 0.050 |
Why?
| | Gastric Emptying | 1 | 2020 | 15 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 11 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2020 | 55 | 0.050 |
Why?
| | Gastroplasty | 1 | 2020 | 28 | 0.050 |
Why?
| | Inventions | 1 | 2019 | 4 | 0.050 |
Why?
| | Epidemiological Monitoring | 1 | 2019 | 8 | 0.050 |
Why?
| | Biomedical Technology | 1 | 2019 | 10 | 0.050 |
Why?
| | Canada | 1 | 2019 | 60 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2019 | 9 | 0.050 |
Why?
| | Gastric Bypass | 1 | 2020 | 57 | 0.050 |
Why?
| | Diffusion of Innovation | 1 | 2019 | 41 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 38 | 0.050 |
Why?
| | Models, Anatomic | 1 | 2019 | 68 | 0.040 |
Why?
| | Obesity, Morbid | 1 | 2020 | 84 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2019 | 128 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 244 | 0.040 |
Why?
| | Internationality | 1 | 2018 | 26 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2018 | 102 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2018 | 112 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 45 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 235 | 0.040 |
Why?
| | Societies, Medical | 1 | 2019 | 214 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 387 | 0.040 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 2017 | 1 | 0.040 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 2 | 0.040 |
Why?
| | Portal Pressure | 1 | 2017 | 6 | 0.040 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2017 | 5 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2018 | 115 | 0.040 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2017 | 7 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 21 | 0.040 |
Why?
| | Disease Progression | 1 | 2019 | 870 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2014 | 9 | 0.030 |
Why?
| | Quality of Life | 1 | 2020 | 747 | 0.030 |
Why?
| | ras Proteins | 1 | 2014 | 13 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 22 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 37 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 109 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 114 | 0.030 |
Why?
| | Piroxicam | 1 | 2013 | 6 | 0.030 |
Why?
| | HT29 Cells | 1 | 2013 | 9 | 0.030 |
Why?
| | Chromones | 1 | 2013 | 10 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2013 | 8 | 0.030 |
Why?
| | Tryptases | 1 | 2013 | 10 | 0.030 |
Why?
| | Morpholines | 1 | 2013 | 16 | 0.030 |
Why?
| | Anticarcinogenic Agents | 1 | 2013 | 18 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 34 | 0.030 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2013 | 38 | 0.030 |
Why?
| | Cell Movement | 1 | 2013 | 119 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 287 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2013 | 232 | 0.030 |
Why?
| | Mutation | 1 | 2014 | 464 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2013 | 399 | 0.030 |
Why?
| | Rectum | 1 | 2011 | 72 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 111 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 563 | 0.030 |
Why?
| | Signal Transduction | 1 | 2013 | 590 | 0.020 |
Why?
| | Mice | 1 | 2013 | 1958 | 0.020 |
Why?
| | Psychotropic Drugs | 1 | 2005 | 30 | 0.020 |
Why?
| | Causality | 1 | 2005 | 60 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2005 | 124 | 0.020 |
Why?
| | Health Surveys | 1 | 2005 | 102 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2005 | 160 | 0.010 |
Why?
| | Comorbidity | 1 | 2005 | 563 | 0.010 |
Why?
| | Animals | 1 | 2013 | 5371 | 0.010 |
Why?
| | Chicago | 1 | 2005 | 957 | 0.010 |
Why?
| | Stroke | 1 | 2005 | 405 | 0.010 |
Why?
|
|
Melson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|